Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.82 |
| ▸ | PIK3C2G | O75747 | 6/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16490566 | 0.93 | PI4KB (0.82) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490355 | 0.92 | PI4KB (0.83) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490384 | 0.92 | PI4KB (0.82) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490567 | 0.91 | PI4KB (0.78) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490521 | 0.90 | PI4KB (1.00) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490440 | 0.90 | PI4KB (0.98) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490545 | 0.89 | PI4KB (0.83) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL17889669 | 0.89 | PI4KB (1.00) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD | |
| SCHEMBL16490549 | 0.88 | PI4KB (0.84) | PI4KBPIK3C2GPIK3CGPIK3CD | |
| SCHEMBL17904448 | 0.88 | PI4KB (0.71) | PI4KBPIK3C2GPIK3CAPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419980-B1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20220017507-A1 | PI-Kinase Inhibitors with Anti-Infective Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-20 | — | — | US | disclosed |
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10428060-B2 | PI-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428060-B2 | PI-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2017147526-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | PIP4K2A, PIP5K1A, PIP4K2C | PI4KB 9/4885PIK3C2G 100/4885PIK3CA 25/4885 |
| US-20220017507-A1 | PI-Kinase Inhibitors with Anti-Infective Activity | PIP4K2A, PIP5K1A, PIP4K2C | PI4KB 9/4885PIK3C2G 98/4885PIK3CA 27/4885 |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | PIP4K2A, PIP5K1A, PIP4K2C | PI4KB 9/4885PIK3C2G 100/4885PIK3CA 25/4885 |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | PIP4K2A, PIP5K1A, PIP4K2C | PI4KB 9/4885PIK3C2G 100/4885PIK3CA 25/4885 |
| US-10428060-B2 | PI-kinase inhibitors with anti-infective activity | PIP4K2A, PIP5K1A, PIP4K2C | PI4KB 9/4885PIK3C2G 100/4885PIK3CA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.